Top-Down Fabricated microPlates for Prolonged, Intra-articular Matrix Metalloproteinase 13 siRNA Nanocarrier Delivery to Reduce Post-traumatic Osteoarthritis
- 19 August 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 15 (9) , 14475-14491
Abstract
Post-traumatic osteoarthritis (PTOA) associated with joint injury triggers a degenerative cycle of matrix destruction and inflammatory signaling, leading to pain and loss of function. Here, prolonged RNA interference (RNAi) of matrix metalloproteinase 13 (MMP13) is tested as a PTOA disease modifying therapy. MMP13 is upregulated in PTOA and degrades the key cartilage structural protein type II collagen. Short interfering RNA (siRNA) loaded nanoparticles (siNPs) were encapsulated in shape-defined poly(lactic-co-glycolic acid) (PLGA) based microPlates (μPLs) to formulate siNP-μPLs that maintained siNPs in the joint significantly longer than delivery of free siNPs. Treatment with siNP-μPLs against MMP13 (siMMP13-μPLs) in a mechanical load-induced mouse model of PTOA maintained potent (65–75%) MMP13 gene expression knockdown and reduced MMP13 protein production in joint tissues throughout a 28-day study. MMP13 silencing reduced PTOA articular cartilage degradation/fibrillation, meniscal deterioration, synovial hyperplasia, osteophytes, and pro-inflammatory gene expression, supporting the therapeutic potential of long-lasting siMMP13-μPL therapy for PTOA.Keywords
Funding Information
- U.S. Department of Health and Human Services (2P30 CA068485-14)
- Rheumatology Research Foundation
- U.S. Department of War (OR130302)
- European Commission (616695)
- U.S. Department of Health and Human Services (R01 CA224241, R01 EB019409, S10RR027631-01, T32GM007347)
- National Science Foundation (2016212929)
- VA Merit Award (BX004151)
- National Science and Engineering Research Council (NSERC)
- European Union????s Horizon 2020 Research and Innovation Programme under the Marie Sklodowska- Curie (754490, 872648)
This publication has 79 references indexed in Scilit:
- MMP13 is a critical target gene during the progression of osteoarthritisArthritis Research & Therapy, 2013
- Alterations in periarticular bone and cross talk between subchondral bone and articular cartilage in osteoarthritisTherapeutic Advances in Musculoskeletal Disease, 2012
- Effects of Glucocorticoid Receptor Small Interfering RNA Delivered Using Poly Lactic-Co-Glycolic Acid Microparticles on Proliferation and Differentiation Capabilities of Human Mesenchymal Stromal CellsTissue Engineering Part A, 2012
- American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and kneeArthritis Care & Research, 2012
- Sustained local delivery of siRNA from an injectable scaffoldBiomaterials, 2012
- Rodent Preclinical Models for Developing Novel Antiarthritic Molecules: Comparative Biology and Preferred Methods for Evaluating EfficacyBioMed Research International, 2010
- Epidemiology of OsteoarthritisClinics in Geriatric Medicine, 2010
- Development of a novel endosomolytic diblock copolymer for siRNA deliveryJournal of Controlled Release, 2009
- Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled studyArthritis Research & Therapy, 2007
- Cartilage destruction by matrix degradation productsModern Rheumatology, 2006